GRI-0621 Has A Unique Profile In The IPF Therapeutic Landscape
Well Suited as a Mono or Combination Therapy.
Unique Mechanism of Action (MOA)
- RARβγ agonist modulates the activity of key immune cells driving fibrosis
- Initiates epithelial cell and lung repair mechanisms
- Upstream of key targets, impacting early and late drivers of fibrosis to interrupt disease progression
Strong Preclinical Data
- GRI-0621 was active across pulmonary, hepatic and renal pre-clinical models of fibrosis
- Pre-clinical data show GRI-0621 outperformed standard of care in pulmonary fibrosis models
- GRI-0621 resolved tissue injury, lowered TGFβ production, myofibroblast activation and ECM deposition
Phase 2a Topline Data
- Positive overall tolerability of oral GRI-0621 consistent with earlier studies of oral tazarotene in over 1,700 subjects
- Robust biomarker data supportive of immunomodulation, fibrosis resolution and alveolar basement membrane repair
- No FVC decline over 12 weeks in patients taking GRI-0621 and standard of care (SOC) compared to SOC alone
GRI-0803 And The Need In Systemic Lupus Erythematosus (SLE)
In development for the treatment of systemic lupus erythematosus.
GRI-0803 is a novel activator of human dNKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus (SLE).
Activation of dNKT leads to a dendritic cell-mediated inhibition of iNKT cells. In our preclinical studies, dNKT activating molecules, GRI-0803 and GRI-0124, were observed to inhibit both murine and human iNKT cells.
Oral administration of these dNKT activating molecules was observed to inhibit lupus nephritis and to significantly improve overall survival.
Key Highlights:
- Targets upstream in the inflammatory cascade providing potential for greater efficacy
- Oral administration in a spontaneous model of lupus nephritis demonstrated significant inhibition of pro-inflammatory cytokines, including IL-6 and IL-17; significant inhibition of autoantibodies; and improvement in overall and proteinuria-free survival
Grab Sources And More Here: GRI Website. GRI Presentation. -----
And as I mentioned above (Nasdaq: GRI) has several potential catalysts on our radar. Take a look:
#1. GRI Potential Catalyst - A Very Low Float Could Create The Environment For Heightened Volatility.
According to info from the Yahoo Finance website, GRI has a pretty low float.
The website reports this profile to have roughly 1.45Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides positive news in the first half of 2026, could it help provide a breakout spark when paired with this volatility potential? -----
#2. GRI Potential Catalyst - A Major Analyst $40 Target Suggests Possible Quadruple-Digit Upside.
Last month, Ascendiant Capital Markets' analyst Edward Woo released an update note on GRI Bio, Inc. (Nasdaq: GRI) with a $40.00 price target.
From Tuesday's closing valuation, that target provides GRI with a potential upside of over 1,500%!
Here are some highlights from the report:
Large market potential for IPF: Idiopathic pulmonary fibrosis is one of the most common and severe form of progressive PF. IPF is on the rise with more than 40,000 new cases diagnosed annually. More than 250,000 Americans are living with PF and ILD, of which IPF affects approximately 140,000 patients in the U.S.
Large market potential for Lupus: The Lupus Foundation of America estimates that 1.5Mn Americans, and at least five Mn people worldwide, have a form of lupus. As many as 24,000 people in the U.S. are diagnosed with the disease each year.
Balance sheet: In Q4, GRI had $8Mn in cash and no debt. In the current Q1, the company raised ~$6Mn. We believe it has enough cash into mid-2027. -----
#3. GRI Potential Catalyst - The Company Announced A Strengthened Balance Sheet And Highlighted Recent Accomplishments.
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Company reported $8.2Mn in cash and cash equivalents at December 31, 2025 and raised additional $6.5Mn in gross proceeds in January 2026
Balance sheet strengthened to fund operations into Q1 2027
Strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis reinforce clinical proof-of-concept and therapeutic differentiation
GRI-0803 focused on autoimmune indications with high unmet need advancing through IND-enabling activities
LA JOLLA, CA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases today summarized recently reported Full Year 2025 financial results, provided an update on the Company’s current cash position and cash runway and summarized key clinical and corporate highlights.
“In 2025, we prioritized disciplined clinical execution and balance sheet strength, delivering compelling clinical data from our lead IPF program which underscores the therapeutic differentiation of GRI-0621,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. “Entering 2026 with a strong cash position, we are focused on advancing GRI-0621 in IPF, progressing GRI-0803 toward the clinic and executing our clinical strategy with capital discipline to drive long-term value creation.”
...
Read the full article here. -----
#4. GRI Potential Catalyst - Recent Phase 2a Positive Study Data Exceeds The Company's Expectations.
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy
LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced additional positive data from its recently completed Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”), further strengthening potential clinical proof-of-concept and reinforcing the therapeutic differentiation of GRI-0621.
Newly reported RNA-sequencing differential gene expression data demonstrate that treatment with GRI-0621 resulted in significant improvement across genes associated with lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar basement membrane and epithelial repair compared to placebo. These findings represent a potential powerful and independent validation of previously reported biomarker, functional and clinical signals from the Phase 2a study.
...
“The data from the Phase 2a study exceed our expectations,” said Marc Hertz, PhD, Chief Executive Officer of GRI Bio. “Across gene expression, serum biomarkers, immune profiles and lung function, we see a remarkably consistent picture emerge. GRI-0621 appears to suppress ongoing injury, reduce fibrosis, and activate mechanisms associated with rebuilding damaged lung tissue. The totality of data generated in this Phase 2a study suggests that GRI-0621 may represent a fundamentally different approach, with the potential to alter the trajectory of disease by promoting repair of damaged lung tissue.”
...
Read the full article here. -----
#5. GRI Potential Catalyst - A Critical New Patent Strengthens The Durability Of The Company's IP Estate.
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases
LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,528,775, providing robust new intellectual property protection for novel compound compositions central to the Company’s platform of immunomodulators.
The newly issued patent includes composition-of-matter claims covering a distinct class of proprietary compounds defined by linked molecular structures that form pyrrolidine, piperidine, or azepane ring systems. These specific molecular configurations represent a key structural advancement and are separate and distinct from patents previously issued to the Company, further strengthening the durability of GRI Bio’s intellectual property estate.
“This patent reflects our disciplined IP strategy and scientific depth,” said Marc Hertz, Chief Executive Officer of GRI Bio. “We have now secured independent protection for a novel and highly valuable subset of our chemistry platform.”
...
Read the full article here. -----
(Nasdaq: GRI) Recap - 5 Potential Catalysts Hit Our Radar
#1. A Very Low Float Could Create The Environment For Heightened Volatility.
#2. A Major Analyst $40 Target Suggests Possible Quadruple-Digit Upside.
#3. The Company Announced A Strengthened Balance Sheet And Highlighted Recent Accomplishments.
#4. Recent Phase 2a Positive Study Data Exceeds The Company's Expectations.
#5. A Critical New Patent Strengthens The Durability Of The Company's IP Estate. -----
It's official. Coverage is now underway on GRI Bio, Inc. (Nasdaq: GRI).
Be on the lookout for updates coming soon. Talk shortly.
Sincerely, Kai Parker StockWireNews
Sources: (1.) Maher, T.M., et al., Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res, 2021. 22(1): p. 197 (2.) Izmirly, P.M., et al., Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol, 2021. 73(6): p. 991.
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 04/08/2026 and ending on 04/08/2026 to publicly disseminate information about (GRI:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the thirty five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (GRI:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/gri-qyw37/#details |
No comments:
Post a Comment